Abstract
Many polymorphs of KFA-1982, an orally active factor Xa (fXa) inhibitor, have been identified and their physicochemical properties have been investigated. Form B was selected as the oral API form because of its superior stability and solubility characteristics. Crystallization conditions for form B were thoroughly investigated including the role of water in hydrate formation and the use of antisolvents and supersaturation in polymorph control.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have